A Phase I Study of Recombinant Human CD4 Immunoglobulin G (rCD4-lgG) in Patients With HIV-Associated Immune Thrombocytopenic Purpura
Phase 1
Completed
- Conditions
- Immune Thrombocytopenic Purpura ( ITP )HIV Infections
- Registration Number
- NCT00002250
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
To test the effectiveness of recombinant human CD4 Immunoglobulin G (CD4-IgG) in the treatment of HIV-associated immune thrombocytopenic purpura in patients with all levels of HIV infection.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of rCD4-IgG in modulating HIV-associated immune thrombocytopenic purpura (HIV-ITP)?
How does recombinant CD4-IgG compare to standard-of-care therapies for HIV-ITP in clinical trials?
Which biomarkers are associated with response prediction to rCD4-IgG in HIV-ITP patients?
What are the known adverse events and management strategies for rCD4-IgG in HIV-ITP treatment?
Are there any combination therapies or competitor drugs for HIV-ITP similar to Genentech's rCD4-IgG?
Trial Locations
- Locations (1)
San Francisco Gen Hosp
🇺🇸San Francisco, California, United States
San Francisco Gen Hosp🇺🇸San Francisco, California, United States